These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

36 related articles for article (PubMed ID: 1146809)

  • 1. Letter: efficient use of heparin as an anticoagulant in blood gas studies.
    Stach PE
    Am J Hosp Pharm; 1975 May; 32(5):455. PubMed ID: 1146809
    [No Abstract]   [Full Text] [Related]  

  • 2. The influence of epsilon-aminocaproic acid derivatives on the anticoagulant activity of heparin.
    Midura-Nowaczek K; Bruzgo I; Worowski K; Roszkowska-Jakimiec W
    Rocz Akad Med Bialymst; 1998; 43():228-31. PubMed ID: 9972059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of r-hirudin vs. heparin on blood-membrane interactions during hemodialysis.
    van Wyk V; Badenhorst PN; Kotzé HF
    Clin Nephrol; 1997 Dec; 48(6):381-7. PubMed ID: 9438098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The significance of TFPI in clotting assays--comparison and combination with other anticoagulants.
    Nordfang O; Kristensen HI; Valentin S; Ostergaard P; Wadt J
    Thromb Haemost; 1993 Sep; 70(3):448-53. PubMed ID: 8259547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pro: heparin is the best anticoagulant for cardiopulmonary bypass.
    Rinder CS
    J Cardiothorac Vasc Anesth; 1996 Oct; 10(6):816-8. PubMed ID: 8910166
    [No Abstract]   [Full Text] [Related]  

  • 6. [The effect of some anticoagulant agents on coronary blood flow].
    Banaszkiewicz W; Kubacki A; Mrozikiewicz A
    Acta Physiol Pol; 1965; 16(6):917-21. PubMed ID: 4161745
    [No Abstract]   [Full Text] [Related]  

  • 7. Is there a real alternative anticoagulant to heparin in continuous treatments?
    Mariano F; Tetta C; Ronco C; Triolo G
    Expert Rev Med Devices; 2006 Jan; 3(1):5-8. PubMed ID: 16359246
    [No Abstract]   [Full Text] [Related]  

  • 8. The use of heparin in preparing samples for blood-gas analysis.
    Higgins C
    MLO Med Lab Obs; 2007 Oct; 39(10):16-8, 20; quiz 22-3. PubMed ID: 18018679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin is an unsuitable anticoagulant for the detection of plasma ammonia.
    Wannasilp N; Sribhen K; Pussara N; Hwanpuch T; Wangchaijaroenkit S; Opartkiattikul N
    Clin Chim Acta; 2006 Sep; 371(1-2):196-7. PubMed ID: 16678809
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of certain anticoagulant drugs on coronary flow in situ].
    Banaszkiewicz W; Kubacki A; Mrozikiewicz A
    Acta Physiol Pol; 1967; 18(1):117-20. PubMed ID: 6031976
    [No Abstract]   [Full Text] [Related]  

  • 11. Heparin and EDTA as anticoagulant differentially affect cytokine mRNA level of cultured porcine blood cells.
    Duvigneau JC; Sipos W; Hartl RT; Bayer M; Moldzio R; Stevenson L; Adair B; Gemeiner M
    J Immunol Methods; 2007 Jul; 324(1-2):38-47. PubMed ID: 17568606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin's endogenous function, primarily anticellular-destructive, incidentally anticoagulant, is dose-, source-, and pH-dependent.
    Saliba MJ
    Thromb Haemost; 1978 Aug; 40(1):200-2. PubMed ID: 31706
    [No Abstract]   [Full Text] [Related]  

  • 13. [Basic principles anticoagulant therapy].
    Mammen EF
    Internist (Berl); 1969 Jan; 10(1):2-8. PubMed ID: 4190310
    [No Abstract]   [Full Text] [Related]  

  • 14. New antithrombin-based anticoagulants.
    Desai UR
    Med Res Rev; 2004 Mar; 24(2):151-81. PubMed ID: 14705167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a new potent heparin. 3rd Communication: Determinations of anticoagulant activity of a new potent heparin preparation by thrombelastography in vitro using citrated dog and human blood.
    Bhargava AS; Freihube G; Günzel P
    Arzneimittelforschung; 1980; 30(8):1256-8. PubMed ID: 7192139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Complement activation in heparin--plasma inhibitory effect of anticoagulants on serum complement activation, 2nd report].
    Kobayashi E; Kitano E; Kondo H; Kitamura H
    Rinsho Byori; 2000 Jan; 48(1):60-6. PubMed ID: 10756677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study of the mechanism of the anticoagulant action of fucoidans].
    Rozkin MIa; Levina MN; Kameneva NS; Usov AI; Efimov VS
    Farmakol Toksikol; 1989; 52(3):48-51. PubMed ID: 2792353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulant property of a semi-synthesized sodium beta-1,4-glucan sulfate.
    Wang ZM; Li L; Li B; Guo SY
    Yao Xue Xue Bao; 2006 Apr; 41(4):323-7. PubMed ID: 16856476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin and low molecular weight heparin in thrombosis and beyond.
    Mousa SA
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Control of heparin and oral anticoagulants, with micromethods: thrombin time, quick determination with addition of protamine].
    Seiler K; Müller G; Duckert F
    Schweiz Med Wochenschr; 1970 Sep; 100(36):1522-8. PubMed ID: 5524716
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.